Health and Healthcare

Friday's Top Biotech and Medical Stocks

Biotechnology

FERMAVIR PHARMACEUTL [FMVR.OB] +19.05%
POLYMEDIX INC [PYMX.OB] +14.29%
KOSAN BIOSCIENCES [KOSN] +11.11%
BIONOVO INC [BNVI.OB] +10.04%
NEURO-HITECH INC [NHPI.OB] +9.01%

Diagnostic Substances

ABAXIS INC [ABAX] +21.00%
INFINITY PHARMACEUTI [INFI] +5.15%
GENE LOGIC INC [GLGC] +4.58%
PONIARD PHARMA [PARD] +4.46%
IDEXX LABS [IDXX] +3.93%

Drug Delivery

NOVADEL PHARMA INC [NVD] +5.23%
ELAN CP PLC ADR [ELN] +3.09%
DELCATH SYSTEMS INC [DCTH] +2.99%
GENEREX BIOTECH CORP [GNBT] +2.92%
BIOVAIL CORP [BVF] +2.42%

Drug Manufacturers

LIGAND PHARM CMN STK [LGND] +4.77%
SPECTRUM PHARMA INC [SPPI] +4.76%
TAPESTRY PHARMA INC [TPPH] +4.25%
MEDICINES CO (THE) [MDCO] +3.89%
ACUSPHERE INC [ACUS] +3.85%

Medical Appliances & Equipment

SIGNALIFE INC [SGN] +11.71%
UROLOGIX INC [ULGX] +11.58%
CANDELA CP [CLZR] +4.43%
THERMAGE, INC. [THRM] +4.01%
ENDOCARE INC [ENDO.OB] +3.41%

Medical Instruments & Supplies

CRYOCOR, INC. [CRYO] +9.53%
BIOMIMETIC THERAPEUT [BMTI] +7.80%
MEMRY CORPORATION [MRY] +6.98%
ENDOLOGIX INC [ELGX] +4.67%
VASCULAR SOLUTIONS [VASC] +3.96%

Medical Laboratories & Research

BIOFORCE NANOSCIENCE [BFNH.OB] +28.57%
GENOMIC HEALTH, INC. [GHDX] +7.47%
SPHERIX INC [SPEX] +3.00%
ALLIANCE IMAGING INC [AIQ] +2.19%
RADNET INC [RDNT.OB] +2.15%

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.